Farnier, M., Marcereuil, D., De Niet, S., Ducobu, J., Steinmetz, A., Retterstøl, K., … Vanderbist, F. (2012). Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia. Clinical Drug Investigation, 32(4), 281–291. https://doi.org/10.2165/11630820-000000000-00000

Farnier, Michel, David Marcereuil, Sophie De Niet, Jean Ducobu, Armin Steinmetz, Kjetil Retterstøl, Leszek Bryniarski, Albert Császár, and Francis Vanderbist. “Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia.” Clinical Drug Investigation 32, no. 4 (April 2012): 281–91. https://doi.org/10.2165/11630820-000000000-00000.

Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstøl K, et al. Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia. Clinical Drug Investigation. 2012 Apr;32(4):281–91.

Farnier, Michel, et al. “Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia.” Clinical Drug Investigation, vol. 32, no. 4, Springer Science and Business Media LLC, Apr. 2012, pp. 281–91. Crossref, doi:10.2165/11630820-000000000-00000.

Farnier M, Marcereuil D, De Niet S, Ducobu J, Steinmetz A, Retterstøl K, Bryniarski L, Császár A, Vanderbist F. Safety of a Fixed-Dose Combination of Fenofibrate/Pravastatin 160 mg/40 mg in Patients with Mixed Hyperlipidaemia. Clinical Drug Investigation. Springer Science and Business Media LLC; 2012 Apr;32(4):281–291.